Search by Drug Name or NDC
NDC 71665-0001-02 CYFENDUS 100 ug/mL Details
CYFENDUS 100 ug/mL
CYFENDUS is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Emergent Product Development Gaithersburg Inc.. The primary component is BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS.
MedlinePlus Drug Summary
What is anthrax? Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides. Cutaneous Anthrax. In its most common form, anthrax is a skin disease that causes skin ulcers and usually fever and fatigue. Up to 20% of these cases are fatal if untreated. Gastrointestinal Anthrax. This form of anthrax can result from eating raw or undercooked infected meat. Symptoms can include fever, nausea, vomiting, sore throat, abdominal pain and swelling, and swollen lymph glands. Gastrointestinal anthrax can lead to blood poisoning, shock, and death. Inhalation Anthrax. This form of anthrax occurs when B. anthracis is inhaled, and is very serious. The first symptoms can include a sore throat, mild fever and muscle aches. Within several days these symptoms are followed by severe breathing problems, shock, and often meningitis (inflammation of the brain and spinal cord covering). This form of anthrax requires hospitalization and aggressive treatment with antibiotics. It is often fatal.
Related Packages: 71665-0001-02Last Updated: 05/19/2024
MedLinePlus Full Drug Details: Anthrax Vaccine
Product Information
NDC | 71665-0001 |
---|---|
Product ID | 71665-001_9b03fee7-6174-4362-9b11-d4c069f3eb3d |
Associated GPIs | |
GCN Sequence Number | 085091 |
GCN Sequence Number Description | anthrax vaccine adsorbed, adjv VIAL 0.5ML/DOSE INTRAMUSC |
HIC3 | W7N |
HIC3 Description | TOXIN-PRODUCING BACILLI VACCINES/TOXOIDS |
GCN | 54529 |
HICL Sequence Number | 049090 |
HICL Sequence Number Description | ANTHRAX VACCINE ADSORBED, ADJUVANTED |
Brand/Generic | Brand |
Proprietary Name | CYFENDUS |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Anthrax Vaccine Adsorbed, Adjuvanted |
Product Type | VACCINE |
Dosage Form | INJECTION, SUSPENSION |
Route | INTRAMUSCULAR |
Active Ingredient Strength | 100 |
Active Ingredient Units | ug/mL |
Substance Name | BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS |
Labeler Name | Emergent Product Development Gaithersburg Inc. |
Pharmaceutical Class | Actively Acquired Immunity [PE], Anthrax Vaccines [Chemical/Ingredient], Live Attenuated Bacillus Anthracis Vaccine [EPC], Vaccines, Attenuated [Chemical/Ingredient] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA125761 |
Listing Certified Through | 2024-12-31 |
Package
NDC 71665-0001-02 (71665000102)
NDC Package Code | 71665-001-02 |
---|---|
Billing NDC | 71665000102 |
Package | 10 VIAL, MULTI-DOSE in 1 CARTON (71665-001-02) / 5 mL in 1 VIAL, MULTI-DOSE (71665-001-01) |
Marketing Start Date | 2023-09-19 |
NDC Exclude Flag | N |
Pricing Information | N/A |